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Specialist respiratory outreach: a case-finding initiative
for identifying undiagnosed COPD in primary care
Emma Ray1,2, David Culliford 1, Helen Kruk1,2, Kate Gillett1,2, Mal North1,2, Carla M. Astles1,2, Alexander Hicks2, Matthew Johnson 1,
Sharon Xiaowen Lin1, Rosanna Orlando1, Mike Thomas 3, Rachel E. Jordan4, David Price 5,6, Mita Konstantin2 and
Tom M. A. Wilkinson 7,8,9✉
COPD remains largely undiagnosed or is diagnosed late in the course of disease. We report findings of a specialist outreach
programme to identify undiagnosed COPD in primary care. An electronic case-finding algorithm identified 1602 at-risk patients
from 12 practices who were invited to attend the clinic. Three hundred and eighty-three (23.9%) responded and 288 were enrolled
into the study. Forty-eight (16.6%) had undiagnosed mild and 28 (9.7%) had moderate airway obstruction, meeting spirometric
diagnostic criteria for COPD. However, at 12 months only 8 suspected COPD patients (10.6%) had received a diagnostic label in their
primary care record. This constituted 0.38% of the total patient population, as compared with 0.31% of control practices, p= 0.306.
However, if all patients with airway obstruction received a coding of COPD, then the diagnosis rate in the intervention group would
have risen by 0.84%. Despite the low take-up and diagnostic yield, this programme suggests that integrated case-finding strategies
could improve COPD recognition.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a common,
serious and disabling lung condition, usually caused by regular
exposure to noxious inhaled agents, particularly tobacco smoke1–3.
It is a preventable and treatable disease, although it is usually
progressive once established2,4,5. It is characterised by persistent
airflow obstruction and persistent respiratory symptoms, including
dyspnoea, cough and sputum production, with episodic acute
exacerbations1,6,7. Guidelines recommend that the diagnosis
should be considered in any patient with suggestive symptoms
and a history of exposure to relevant risk factors, such as cigarette
smoke and indoor biomass cooking fumes. Persistent obstruction
post bronchodilator needs to be demonstrated to confirm the
diagnosis1,2. There is, however, consistent and ongoing evidence of
major under-diagnosis of COPD globally including in the UK8–10.
Based on epidemiological surveys, it is estimated that the true
global prevalence of COPD is 11.7% (95% confidence interval (CI)
8.4–15.0%), yet the proportion of the population told that they
have COPD is <6% in most national data sets, and often as low as
2–3%, reflecting widespread under-recognition and under-
diagnosis. The reasons for under-diagnosis are varied: some
patients may not seek medical care due to mild symptoms, some
may tolerate symptoms rather than seeking help or may choose to
self-manage, and some may have difficulty accessing medical
care11–14. However, many patients will consult with their primary
care clinicians for persistent respiratory symptoms, or for acute
episodes, representing unrecognised exacerbations, and may
receive treatment (e.g. antibiotics, bronchodilators, corticosteroids,
antitussives) without a diagnosis being made or diagnostic
investigations for the underlying problem undertaken15.
Although COPD is not curable, there are a number of cogent
reasons for encouraging an early diagnosis. First, as a preventable
progressive condition, recognition of early disease allows target-
ing of preventative measures to reduce disease progression,
notably interventions to reduce exposures, such as smoking
cessation and reduction of exposure to airborne pollutants,
including indoor biomass fuel fumes2,16. There is some evidence
to suggest that demonstration of lung damage by spirometry can
support the motivation and success of smoking cessation17. Other
relevant lifestyle and prevention measures for patients with early
COPD include diet and exercise advice and appropriate vaccina-
tion and referral for pulmonary rehabilitation (PR) offered in a
variety of models where appropriate1,18–23. Additionally, although
pharmacotherapy is not curative, effective medication can reduce
symptoms, exacerbations, lung function decline and mortality as
well as improving and quality of life1,2,24.
Although guidelines agree on the desirability of early diagnosis,
the best way to achieve this is unclear. A US systematic review
concluded that population-level screening with spirometry in
asymptomatic adults was not a viable strategy logistically, or
economically, but did encourage clinicians to ‘pursue active case-
finding for COPD in patients with risk factors or respiratory
symptoms25. All active case-finding initiatives rely on identification
of those at risk of COPD for screening, and a number of
approaches have been investigated, including targeting smokers
with screening questionnaires and then inviting those screening
positive to attend for diagnostic spirometry26–32. Several COPD
risk-prediction models have been proposed33,34, but variations in
methods and a lack of prospective randomised controlled trials to
confirm the viability, clinical and cost effectiveness of these
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approaches has hindered adoption into routine clinical practice. In
the UK, a COPD risk score for identifying currently undiagnosed
patients based on information present in the routine primary care
clinical record (the TargetCOPD score) has recently been devel-
oped and successfully implemented35. This algorithm uses
individual patient information from the medical record on age,
smoking status, dyspnoea consultations, prescriptions for salbu-
tamol and prescriptions for antibiotics to generate an individual
COPD risk score and has the potential to be electronically
automated and applied to primary care electronic records.
In the current pressurised clinical climate, many primary care
centres are stretched in coping with rising clinical workload and
may be reluctant to take on additional screening activities; an
alternative approach is using ‘interface’ teams, such as outreach
specialist groups, to support general practice (GP) and provide
integrated care between hospital and community-based sectors.
Such initiatives do, however, need to be prospectively evaluated
in pilots for acceptability, clinical and cost effectiveness prior to
wider implementation.
We report the prospective analysis of a pilot clinical service set
in routine UK GP, using the TargetCOPD score applied electro-
nically to the primary care routine electronic medical record, to
identify currently undiagnosed patients at risk of COPD and invite
them for diagnostic assessment at their GP practice by a specialist
outreach nursing team with feedback to practices. An assessment
of the new COPD diagnosis rate in participating centres in the year
following the intervention was made, with comparison to the
diagnosis rate in similar patients receiving usual care in matched




Twelve practices were included in the study, with list sizes of
8196–15,422, combined total patient population 147,673, with a
mean (range) prevalence of diagnosed COPD prior to the study
of 1–3%.
The electronic score identified 2213 at-risk patients (Fig. 1). The
lead GPs assessed the list and excluded 611 patients considered
inappropriate to invite for assessment. One thousand six hundred
and two patients were sent postal invitations to attend for
assessment, and 383 (23.9%) patients responded. Seventy-six
patients who responded were not included in the study because
they declined to participate, were uncontactable or were found to
be not eligible. Four further patients were excluded because they
were unable to perform spirometry and 15 patients did not attend
their booked appointment. In total, 288 (male 51%, mean age 63,
standard deviation (SD)= 6.71 years) attended the case-finding
clinic and provided informed consent. Of these, 76 (26.4%) met
the UK spirometric diagnostic criteria for COPD (post-bronchodi-
lator ratio <0.70 and concurrent respiratory symptoms) of whom
48 (63.1%) had mild airflow obstruction (GOLD 1: percentage of
forced expiratory volume in 1 s (FEV1%) predicted ≥80%), 28
(36.8%) moderate (GOLD 2: FEV1% predicted ≥50–<80% airflow
obstruction) and none had severe/very severe airflow obstruction.
In a sensitivity analysis using age-sex specific ‘lower limit of
normal’ (LLN) criteria (Global Lung Initiative equations36), fewer
patients met diagnostic criteria for COPD (39, 13.5%).
In comparison with those without airflow obstruction, the
patients with suspected COPD reported more chronic cough (52,
68.4% versus 110, 51.9%, Chi-squared test, p= 0.013), dyspnoea
(42, 55.3% versus 98, 46.2%, Chi-squared test, p= 0.176), wheeze
Fig. 1 Patient flow through the study. Indicated is the recruitment of general practices and patients. It also shows the number of GP
practices that agreed to participate and the number of patients identified, invited, responded, booked and recruited. Numbers of patients
determined to have airflow obstruction by spirometry and respiratory symptoms are also displayed.
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(43, 56.6% versus 75, 35.4%, Chi-squared test, p= 0.001) and
chronic sputum (29, 38.2 versus 60, 28.3%, Chi-squared test, p=
0.111). Fifty patients (66.7%) with suspected COPD and 108
(50.9%, Chi-squared test, p= 0.019) of patients with no suspected
COPD reported significant dyspnoea related to physical activity
(Medical Research Council dyspnoea (MRC) scale ≥2). Among
breathless patients (MRC ≥ 2), there was no difference in mean
body mass index (BMI) between those with suspected COPD and
those without (mean, SD: 29.5 (6.2) versus 30.9 (5.8), 95% CI for
difference: [−0.7, 3.4], t test, p= 0.209), with only 3 out of 50 and 5
out of 108, respectively, being morbidly obese (BMI ≥ 40).
A previous diagnosis of asthma was more common in patients
with suspected COPD (34, 44.7% versus 51, 24.1%, Chi-squared
test, p= 0.001). Current smoking was more common in patients
with suspected COPD than without (23, 30.3% versus 43, 20.3%,
Chi-squared test, p= 0.079) as was a higher mean pack-year
history (29.3, interquartile range (IQR) [15, 45] versus 17.4, IQR [7,
33.5], Mann–Whitney U test, p < 0.001). Mean FEV1 was also lower
in those with suspected COPD (2.38 L, SD 0.66 versus 2.75 L, SD
0.68, t test, p < 0.001).
New COPD diagnoses in the subsequent 12 months
In the year following the intervention in the active practices, 57
patients received a new diagnosis of COPD in their medical record
from a base population of 14,818 ever smokers in the 40–79-year
age group, equating to 0.38%. In the control practices, there were
46 new diagnosis in 14,638 (0.31%), (Chi-squared test, p= 0.306).
This equates to a COPD new diagnosis rate per 1000 patients in
the overall practice list of 3.84 in the active and 3.14 in the control
practices. Further analysis of the newly diagnosed cases in the
active practices revealed that only 8 of the 76 patients with
obstructive spirometry on assessment and suspected COPD
subsequently received a new diagnosis of COPD recorded in the
electronic medical record with the other 49 new diagnoses made
in patients who did not attend the diagnostic assessments.
Other effects of the programme
In addition to new diagnosis, we assessed other clinical
consequences of the assessment in the active practices. Recom-
mendations for further action by the GPs were made in 112
(38.9%) patients, 61 (80.3%) of patients with suspected COPD and
51 (24.0%) of patients with no COPD. This included smoking
cessation, weight loss clinics and referral to respiratory specialist
medical teams. For those with suspected COPD (N= 76, 26.4%),
the study team recommended further clinical investigations that
included: chest X-rays (56, 73.7%) and electrocardiogram (11,
14.5%), sputum cultures (4, 5.3%) and bloods tests (34, 44.7%) and
specialist referral (n= 22, 28.9%). Treatment recommendations
were made for 119 (41.3%) patients, the majority being inhaled
medications with adjuncts (spacer devices), plus intranasal
steroids in 7 cases while 2 patients were recommended a
proton-pump inhibitor.
All active smokers (n= 66) received brief smoking cessation
advice with an offer of specialist smoking service referral, which
was accepted by 6 (26.1%) patients with suspected COPD versus
18 (41.9%) of patients with no COPD. Referrals to a weight loss
clinic were accepted by more patients with no COPD than those
with suspected COPD (12, 5.6% versus 2, 2.6%) despite BMI being
similar between groups (Table 1). PR referral was agreed with 12
(15.8%) patients with suspected COPD and with 3 (1.4%) patients
with no COPD for reasons including bronchiectasis.
Cost analysis
The mean total costs (primary and secondary care attendances)
for respiratory-related issues per patient for the 12 months prior to
the baseline visit and at the 12 months follow-up point was
collected. In total, 33 patients were lost to follow-up at the 12-
month follow-up point. At the baseline visit, health care costs for
the previous 12 months were lower for those with suspected
COPD (£43.69) versus those with no COPD (£50.50) (see Table 2).
Costs in the group with no COPD was driven by 6 outliers who had
more frequent contact with the 111 NHS health-support helpline
and Emergency Department episodes. When we excluded these
outliers, the costs were similar between the groups: no COPD
(£45.31) versus suspected COPD (£43.69). In the 12 months
following baseline, mean costs were higher in the suspected
COPD group (£60.42 versus £46.15, Mann–Whitney U, p= 0.001),
reflecting the cost of additional tests and referrals.
The costs of providing the intervention, excluding OPC costs,
were estimated as £57.19 per patient assessed, excluding
premises overhead costs and consumables. This is based on
the costs of providing the appropriately skilled nurse (UK salary
Band 6) conducting the clinic appointment, lasting 1 h 20min per
patient including face-to-face and administrative time. With 288
patients participating in the study, the total staff cost for the
intervention was £16,470. This equates to cost per new COPD
diagnosis in the practice of £288.90 and costs per patient with
confirmed post-bronchodilator airflow obstruction at assessment
of £216.70.
Patient feedback
Patient feedback about the case-finding clinic was sought via a
self-reported questionnaire. In total, 285 were included in this
analysis and 3 were lost to follow-up. Many (161, 57.5%) reported
concerns on receiving the invitation, although most (147, 53.3%)
were not surprised to receive it. Despite all patients (100%, n=
285) reporting feeling concerned about attending the clinic, 99%
(283) reported that attending the clinic was a positive experience
and 80% (223) reported that it had made them think about their
health and 94.3% (265) reported feeling supported by their GP
practice. Further in-depth analysis on patient’s feelings and
experiences of attending the clinic has been captured in the
qualitative sub-study37.
DISCUSSION
Despite calls for identifying undiagnosed COPD patients earlier in
order to instigate preventative and therapeutic interventions to
improve health and retard disease progression, the optimal way of
achieving this aim remains unclear9. This is particularly true when
health resources are limited and primary care teams under
pressure38. A viable focus for COPD case finding is to concentrate
on the demographic group with relevant exposures who are
already known to the medical system and who are receiving
treatments for acute and on-going respiratory episodes that
plausibly could relate to undiagnosed COPD2. In this initiative, we
aimed to prospectively evaluate the effectiveness and accept-
ability of a specialist outreach team identifying and assessing
patients in the community in collaboration with their usual
primary care health team. The aim of the initiative was not to
replace but to augment the usual primary care service and to
provide a convenient and seamless clinical service to at-risk
patients.
In our approach, we electronically applied a previously
internally validated risk score to routine computerised health
records in primary care to identify possible undiagnosed COPD
cases39. A total of 1602 patients were identified and felt to be
appropriate by the GP and received an invitation letter to attend
the clinic, of whom 24% of patients invited responded positively
and 18% attended and were assessed. The response rate
reported in our study is similar to that of other well-reported
case-finding trials for COPD8,35,38. While it is difficult to make
comparisons to other conditions because of the unique study
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design and disease focus, the response rate in case finding for
COPD studies is markedly lower when compared to diabetes
case-finding research studies for example. Indeed, Snijder et al.
and Greaves et al. reported 55 and 60.6% response rates
consecutively to invitation for diabetes screening using case-
finding methods40,41.
Possible reasons for the low response rate in our research may
be due to denial of symptoms particularly if the symptoms are
Table 1. Patient characteristics.
Variable All observations Suspected COPD COPD not
suspected
Missing values p valuec
Participants, n (%) 288 (100.0) 76 (26.4) 212 (73.6)
Age in years, mean (SD) 63.1 (6.7) 63.6 (6.0) 62.9 (7.0) 0.421
Male, n (%) 146 (50.7) 43 (56.6) 103 (48.6) 0.232
Ethnicity, n (%) 0.394
Caucasian 283 (98.3) 74 (97.4) 209 (98.6)
Asian 2 (0.7) 1 (1.3) 1 (0.5)
Afro-Caribbean 1 (0.3) 0 (0.0) 1 (0.5)
Other 2 (0.7) 1 (1.3) 1 (0.5)
BMI kg/m2, mean (SD) 29.2 (5.3) 28.5 (5.6) 29.5 (5.2) 0.188
Practice IMD decile (median, IQR) 9 (8,10) 9 (8,10) 9 (8,10) n/a
Smoking status (n, %) 0.076
Current smoker 66 (22.9) 23 (30.3) 43 (20.3)
Ex-smoker 222 (77.1) 53 (69.7) 169 (79.7)
Smoking pack years (median, IQR) 20 (8,36) 29.3 (15,45) 17.4 (7,33.5) <0.001
Symptoms, n (%)
Cough 162 (56.3) 52 (68.4) 110 (51.9) 0.013
Dyspnoea 140 (48.6) 42 (55.3) 98 (46.2) 0.176
Wheeze 118 (41.0) 43 (56.6) 75 (35.4) 0.001
Sputum 89 (30.9) 29 (38.2) 60 (28.3) 0.111
MRC breathlessness score, n (%) 287 75 212 1 0.060
1 129 (44.9) 25 (33.3) 104 (49.1)
2 119 (41.5) 34 (45.3) 85 (40.1)
3 27 (9.4) 12 (17.4) 15 (7.1)
4 11 (3.8) 4 (5.3) 7 (3.3)
5 1 (0.3) 0 (0.0) 1 (0.4)
FENO (median, IQR) 21 (13,33) 22 (12,36) 21 (14,33) 64 0.568
FEV1 litres, mean (SD) 2.65 (0.70) 2.38 (0.66) 2.75 (0.68) 3 <0.001
FEV1 % predicted (median, IQR) 99 (87,109) 87.5 (74,98) 104 (92,113) 3 <0.001
FEV1/FVC ratio (median, IQR) 74 (69,79) 65 (60,68) 77 (73,80.5) 3 <0.001
FEV1/VC ratio (median, IQR) 76 (70,81) 66 (59.5,69) 79 (75,83) 19 <0.001
FEF 25–75% predicted (median, IQR) 62 (45.5,82) 38 (27.3,46) 71 (57,90) <0.001
Co-morbidities, n (%)
Respiratory tract infection in the past 12 months 67 (23.3) 18 (23.7) 49 (23.1) 0.919
Asthma 85 (29.5) 34 (44.7) 51 (24.1) 0.001
Depression or anxiety 70 (24.3) 17 (22.4) 53 (25.0) 0.646
Gastro-oesophageal reflux disease (GORD) 39 (13.5) 8 (10.5) 31 (14.6) 0.371
Endocrine diseasea 60 (20.8) 20 (26.3) 40 (18.9) 0.170
Cardiac diseaseb 49 (17.0) 12 (15.8) 37 (17.5) 0.741
Chronic rhino-sinusitis 16 (5.6) 2 (2.6) 14 (6.6) 0.195
Allergic rhinitis 16 (5.6) 7 (9.2) 9 (4.2) 0.105
Pneumonia 8 (2.8) 3 (3.9) 5 (2.4) 0.470
Data are presented as n (%), mean (standard deviation) or median (interquartile range), unless otherwise stated.
IMD index of multiple deprivation (a weighted standardised measure of socioeconomic status), BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC
forced vital capacity.
aEndocrine disease is defined as either of diabetes mellitus or hypothyroidism.
bCardiac disease is defined as any of ischaemic heart disease, hypocholesterolaemia, myocardial infarction or atrial fibrillation.
cAll p values computed using tests appropriate for the type and distribution of each variable: t test for age, BMI, FEV1 (litres); Mann–Whitney U test for smoking
pack-years, FEV1 %predicted, FEV1/FVC ratio, FEV1/VC ratio, FEF 25–75 %predicted; Chi-squared test for sex, ethnicity, smoking status, MRC breathlessness
score, all symptoms and all comorbidities.
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mild and not limiting daily activities. People may also avoid
addressing their lung health due to the potential stigma of having
a chronic lung disease caused by their tobacco dependency42,43.
Potential cost implications such as an increase in life and travel
insurance, as well as the cost of prescriptions may also be a factor
to decline participation44. Another barrier might be that smokers
who may not be susceptible to quitting may be concerned that
they will receive judgemental and negative smoking cessation
advice from the health care professional screening them45.
Patients who responded and were enrolled into the study were
generally older and possibly found it more convenient to attend a
potentially lengthy appointment, and younger working patients
may have had barriers to attendance and so been under-
represented. Future clinics could potentially offer appointments
in the evenings and at the weekend. Further research should also
provide invitees the opportunity to explain why they do not want
to attend so that we can better understand the barriers to uptake.
Of those attending for assessment, 26% had post-
bronchodilator obstruction on quality-assured spirometry and
respiratory symptoms, consistent with COPD. However, only 57
patients in the practices received a diagnosis of COPD in the
medical records over the next 12 months, and only 8 of these new
diagnoses came in the group undergoing assessment. Conse-
quently, only 1 in 10 of the patients with suspected COPD on
assessment received a subsequent COPD diagnosis from their
primary care team. The reasons why so few of those identified by
the assessment received a diagnosis are not clear and should be a
focus in future research, but previous studies have also noted
this issue.
It is noteworthy that the majority of cases identified as
suspected COPD had mild airflow obstruction, with a lower
proportion meeting ‘LLN’ criteria for COPD, implying that an older
and relatively mild, early COPD population were being identified.
It is plausible that the primary care teams were reluctant to apply
the diagnostic label of COPD to these milder cases because of the
perceived extra workload and perception that the current COPD
caseload is already not being managed well46. We quantified the
new COPD diagnosis rate in control practices, which was slightly
lower than that in our active practices (0.31 versus 0.38%),
implying that there is a small but detectable incremental benefit
on diagnostic rates of the outreach programme. If all 76 of those
who were suspected of having COPD on assessment had received
a coding of COPD, then the diagnosis rate in the intervention
group would have risen from 0.38% to 0.84%. However, as
practices were not randomised to the intervention or control arm,
we also cannot be sure that there were no confounding factors at
either practice or individual level. The assessment-to-diagnosis
yield of 27% we achieved is that predicted from the diagnostic
score used, with the number of diagnostic assessments needed
per case detected being estimated as 4 (3–7), at the risk threshold
of 22.5% used to select patients33.
In addition, we found that there were a number of potentially
beneficial health interventions made for participants in the
programme in addition to making a new COPD diagnosis. These
included health promotion interventions such as smoking
cessation, dietary interventions and PR, as well as recommenda-
tions for further assessment in case of diagnostic uncertainty.
These potential benefits occurred in the group with no COPD as
well as in those with suspected COPD, who were the focus of the
project.
In terms of acceptability to patients, the programme was
generally well received; although many patients reported an initial
anxiety on receiving the invite, most who attended found the
process valuable and beneficial. This reflects the findings of a
qualitative sub-study that was conducted to understand the
barriers to acceptance of diagnostic case finding in at-risk patients
in primary care and is reported elsewhere37. Although not formally
assessed, the GPs, nurses and administrative staff in the
participating practices also found the programme valuable and
appreciated the support provided by the visiting team. The
intervention had associated staffing costs, which we calculated as
being approximately £220 per case of suspected COPD identified,
which needs to be balanced against the potential cost savings of
better management of the newly diagnosed COPD cases and
indeed the health benefits of other patients undergoing assess-
ment. These were not possible to estimate in this study.
There are, however, a number of factors that limit the potential
of using this model in wider settings. First, as only a quarter of
those identified by the score and were invited to attend took up
the opportunity, this implies that, even when provided in a local
setting, such a service may not be attractive to the majority of at-
risk patients. An alternative approach might be that practices
independently run the case-finding algorithm on their clinical
database in order to identify patients at risk of having COPD. They
could then either invite patients to attend for diagnostic
spirometry or add a flag on the patients’ records to allow for
future opportunistic screening for COPD, so that when they
subsequently attend for medical care (possible for respiratory
problems), the attending clinicians are made aware that this
patient is at risk and may need further investigations beyond the
treatment of the presenting acute episode.
Second, although the information on the assessment was fed
back to the practice staff, only 8 of the 76 patients (10.6%) with
post-bronchodilator obstruction at assessment subsequently
received a primary care diagnosis of COPD, so further work is
needed to understand the reluctance to formally apply a
diagnostic label COPD and the effects of the assessment on the
appropriateness of their subsequent management. Despite the
study team communicating individual findings with the GP
practices, it is possible that intense workload pressures in primary
care may have impeded documentation of a formal diagnosis46,47.
In addition, while the GP practice record is a rich source of clinical
data, it is primarily for care purposes, and thus when used in
research settings can result in inaccuracies and complications with
analysis47. Clinicians in our project may plausibly have been
reluctant to assign the diagnostic term COPD because of the
potential impact to the individual and to the practice workload48.
Additionally, the onus was placed on the patient to make a follow-
up appointment with the GP to discuss the findings, therefore if
they did not attend the opportunity to confirm the diagnosis may
have been missed.
In conclusion, we report the results of a specialist outreach
programme to identify undiagnosed COPD in primary care by
generating an ‘at-risk’ list by the electronic application of a
validated screening score to the computerised routine patient
records and inviting those identified to an assessment by a
visiting specialist nursing team in their usual GP surgeries. We
found a low response rate, with approximately a quarter of
identified at-risk patients attending the assessment, but those
who attended found it valuable. For most patients, some health
actions were taken, particularly health promotion activities. In
total, 76 of those assessed had post-bronchodilator airflow
obstruction consistent with COPD, although most had mild
obstruction, and a lower proportion met ‘LLN’ criteria for COPD.
Only 10% of those with airflow obstruction subsequently
Table 2. Summary of patient costs.
No COPD Suspected COPD
Baseline number of patients 212 76
Pre-baseline 12-month cost (mean) £50.50 £43.69
Follow-up number of patients 190 65
Follow-up total cost (average) £55.21 £60.42
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received a primary are diagnostic label, for reasons that are not
clear. The overall new COPD diagnostic rate in the participating
practices was slightly (but not statistically significant given the
sample size) higher than that in control practices, implying that
implementation of the programme could result in a small
benefit to COPD new diagnosis rate. Although the results do not
justify wider implementation of this model of case finding in its
current format, further investigation of the use of ‘interface’
specialist outreach services and of electronic risk-profiling using
primary care medical records is justified; however, the longer-




The specialist team comprised of respiratory nurse specialists based at
Southampton General Hospital, UK, with clinical support from hospital
chest physicians and a General Practitioner with a specialist interest in
respiratory medicine. In total, 12 local GP surgeries agreed to participate in
the programme from rural and urban settings and a broad range of
deprivation profiles. The practices agreed for the team to apply the
algorithm to the electronic patient medical records, to send mailed
invitations for screening at the surgery for those identified as being at risk,
to provide use of their premises for the diagnostic sessions and to receive
information and recommendations from the outreach team. The outreach
team did not make a definitive diagnosis or initiate treatment but provided
the usual clinical team with the results of their assessments and any
recommendations for treatment, further investigation or referral.
The electronic record search was made by Optimum Patient Care (OPC),
a non-profit social enterprise working with primary care to improve the
management of patients with chronic diseases through quality improve-
ment programmes and ethically approved research (https://
optimumpatientcare.org). Lists of Read Codes related to the risk score
were collated by the study team with support from primary care physicians
and provided to OPC in order to complete the search. A COPD risk
threshold of 22.5% as estimated by the algorithm was implemented based
on the original modelling by the Target COPD team and following piloting
of a 25% cut-off, which identified higher numbers of patients but less cases
of COPD39. We therefore determined that the 22.5% cut-off would provide
the best positive predictive value to more accurately identify patients with
COPD to balance the risk of ‘missing’ people who did have COPD, versus
minimising the proportion of ‘false positives’ and to make the intervention
efficient and acceptable, minimising unproductive staff workload, as well
as the potential inconvenience and anxiety caused to patients.
The identified population was then sent a postal invitation to attend for
assessment with an explanation of the study (Supplementary Fig. 1). All
eligible participants who responded to invitation by post attended a 60-
min case-finding clinic at their GP practice, where the outreach team
nurses obtained written informed consent for anonymised data to be used
in the prospective analysis, obtained a clinical history, administered
questionnaires and performed quality-assured spirometry. Study eligibility
criteria included being registered with the participating practices from 1
January 2015 or before, age ≥40 and ≤79 years, no previous diagnosis of
COPD, smoker or ex-smoker and able to complete spirometry testing. The
assessment consisted of demography, height, weight, blood pressure,
medical and smoking history, spirometry with reversibility to 400 µcg of
salbutamol via a metered dose inhaler and spacer device (Microlab®
spirometer, ERS standards), fractional exhaled nitric oxide (NIOX Vero®) and
oxygen saturation (Nonin Onyx Vantage®). To reduce the potential impact
that smoking tobacco has on the lung function tests, we asked patients to
refrain from smoking prior to the appointment and accepted patients’ self-
reported non-smoking status. Questionnaires completed were: MRC scale49
and EuroQOL (EQ-5D) questionnaire50. Additionally, a patient experience
feedback questionnaire was designed to capture participant views on
being invited and attending the clinic. At the end of the appointment, the
findings were discussed with the patient and brief health advice on
smoking, diet and exercise provided where appropriate. When COPD was
suggested, or diagnostic uncertainty existed, patients were asked to
arrange a follow-up appointment with their GP. The team aimed to hold
meetings with the GP and practice nurse to discuss findings, and when not
possible, a full written summary was provided, including recommendations
for treatment, further investigations or referral. Recruitment occurred
between January 2017 and January 2018. Those attending were followed
up with postal questionnaires at 3 and 12 months.
Ethics approval was provided by Southampton B Ethics Committee (16/
SC/0629), and the trial is registered on ClinicalTrials.gov (ID: NCT03355677).
Data analysis
To estimate the incremental diagnostic yield produced by the intervention
over usual care, we quantified the new COPD diagnosis rate in matched
control practices. Control practices were drawn from the OPC practice
portfolio, matched to active sites using practice list size, baseline COPD
and asthma diagnostic register rates, gender, age and index of multiple
deprivation profiles (Supplementary Table 1). Other than anonymised data
extraction, no additional clinical care or feedback to the clinical team
occurred in the control practices. Using pseudo-anonymised data, the
algorithm was applied electronically in the control practices to identify
undiagnosed patients with similar risk profiles as in the active practices,
and the COPD diagnosis rate in these patients over the next 12 months
was ascertained from the medical record.
Statistical analysis
Summary statistics are reported for demographic data. Comparisons
between the active and control groups were made using Mann–Whitney U
test or t test as appropriate for continuous variables and the Chi-squared
test for categorical variables, using a two-sided 5% significance level.
Statistical analyses were performed using R (R Core Team, R Foundation for
Statistical Computing, Vienna, Austria) and SPSS version 24 (SPSS software,
IBM Corp., Armonk, NY). A comparison of health care costs for respiratory
issues in the 12 months preceding and in the 12 months following the
intervention was made in the study patients undergoing assessment,
including primary care costs (GP and nurse appointments, investigations)
and secondary care costs (outpatient, A&E, inpatient), using patient recall
at the baseline visit and at the 12 months. Unit costs were referenced from
the ‘National Schedule of Reference Costs - Year 2015-16 - NHS trusts and
NHS foundation trusts’ and adjusted for the relevant time.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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